vs
Side-by-side financial comparison of JFrog Ltd (FROG) and Guardant Health, Inc. (GH). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $145.3M, roughly 1.9× JFrog Ltd). JFrog Ltd runs the higher net margin — -10.5% vs -45.7%, a 35.2% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 25.2%). JFrog Ltd produced more free cash flow last quarter ($49.9M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 20.4%).
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
FROG vs GH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $145.3M | $281.3M |
| Net Profit | $-15.2M | $-128.5M |
| Gross Margin | 77.9% | 64.6% |
| Operating Margin | -14.7% | -43.0% |
| Net Margin | -10.5% | -45.7% |
| Revenue YoY | 25.2% | 39.4% |
| Net Profit YoY | 34.4% | -15.8% |
| EPS (diluted) | $-0.13 | $-1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $145.3M | $281.3M | ||
| Q3 25 | $136.9M | $265.2M | ||
| Q2 25 | $127.2M | $232.1M | ||
| Q1 25 | $122.4M | $203.5M | ||
| Q4 24 | $116.1M | $201.8M | ||
| Q3 24 | $109.1M | $191.5M | ||
| Q2 24 | $103.0M | $177.2M | ||
| Q1 24 | $100.3M | $168.5M |
| Q4 25 | $-15.2M | $-128.5M | ||
| Q3 25 | $-16.4M | $-92.7M | ||
| Q2 25 | $-21.7M | $-99.9M | ||
| Q1 25 | $-18.5M | $-95.2M | ||
| Q4 24 | $-23.2M | $-111.0M | ||
| Q3 24 | $-22.9M | $-107.8M | ||
| Q2 24 | $-14.3M | $-102.6M | ||
| Q1 24 | $-8.8M | $-115.0M |
| Q4 25 | 77.9% | 64.6% | ||
| Q3 25 | 77.4% | 64.7% | ||
| Q2 25 | 76.3% | 65.0% | ||
| Q1 25 | 75.3% | 63.3% | ||
| Q4 24 | 75.4% | 61.6% | ||
| Q3 24 | 75.0% | 61.1% | ||
| Q2 24 | 78.8% | 59.1% | ||
| Q1 24 | 79.5% | 61.2% |
| Q4 25 | -14.7% | -43.0% | ||
| Q3 25 | -15.8% | -37.3% | ||
| Q2 25 | -20.4% | -45.9% | ||
| Q1 25 | -18.8% | -54.6% | ||
| Q4 24 | -21.9% | -62.4% | ||
| Q3 24 | -27.4% | -61.3% | ||
| Q2 24 | -18.6% | -56.8% | ||
| Q1 24 | -16.6% | -59.2% |
| Q4 25 | -10.5% | -45.7% | ||
| Q3 25 | -12.0% | -35.0% | ||
| Q2 25 | -17.0% | -43.0% | ||
| Q1 25 | -15.1% | -46.8% | ||
| Q4 24 | -20.0% | -55.0% | ||
| Q3 24 | -21.0% | -56.3% | ||
| Q2 24 | -13.9% | -57.9% | ||
| Q1 24 | -8.8% | -68.2% |
| Q4 25 | $-0.13 | $-1.01 | ||
| Q3 25 | $-0.14 | $-0.74 | ||
| Q2 25 | $-0.19 | $-0.80 | ||
| Q1 25 | $-0.16 | $-0.77 | ||
| Q4 24 | $-0.21 | $-0.90 | ||
| Q3 24 | $-0.21 | $-0.88 | ||
| Q2 24 | $-0.13 | $-0.84 | ||
| Q1 24 | $-0.08 | $-0.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $704.4M | $378.2M |
| Total DebtLower is stronger | — | $1.5B |
| Stockholders' EquityBook value | $887.4M | $-99.3M |
| Total Assets | $1.3B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $704.4M | $378.2M | ||
| Q3 25 | $651.1M | $580.0M | ||
| Q2 25 | $611.7M | $629.1M | ||
| Q1 25 | $563.5M | $698.6M | ||
| Q4 24 | $522.0M | $525.5M | ||
| Q3 24 | $467.8M | $585.0M | ||
| Q2 24 | $591.3M | $933.7M | ||
| Q1 24 | $579.6M | $1.0B |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $887.4M | $-99.3M | ||
| Q3 25 | $859.4M | $-354.5M | ||
| Q2 25 | $826.5M | $-305.5M | ||
| Q1 25 | $800.0M | $-250.8M | ||
| Q4 24 | $773.5M | $-139.6M | ||
| Q3 24 | $756.2M | $-60.1M | ||
| Q2 24 | $721.4M | $-1.6M | ||
| Q1 24 | $707.8M | $68.3M |
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.1B | $1.5B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.0B | $1.6B | ||
| Q1 24 | $997.1M | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $50.7M | $-26.4M |
| Free Cash FlowOCF − Capex | $49.9M | $-54.2M |
| FCF MarginFCF / Revenue | 34.3% | -19.3% |
| Capex IntensityCapex / Revenue | 0.6% | 9.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $142.3M | $-233.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $50.7M | $-26.4M | ||
| Q3 25 | $30.2M | $-35.4M | ||
| Q2 25 | $36.1M | $-60.3M | ||
| Q1 25 | $28.8M | $-62.7M | ||
| Q4 24 | $49.1M | $-64.5M | ||
| Q3 24 | $27.6M | $-51.1M | ||
| Q2 24 | $16.7M | $-94.0M | ||
| Q1 24 | $17.5M | $-30.3M |
| Q4 25 | $49.9M | $-54.2M | ||
| Q3 25 | $28.8M | $-45.8M | ||
| Q2 25 | $35.5M | $-65.9M | ||
| Q1 25 | $28.1M | $-67.1M | ||
| Q4 24 | $48.5M | $-83.4M | ||
| Q3 24 | $26.7M | $-55.3M | ||
| Q2 24 | $16.0M | $-99.1M | ||
| Q1 24 | $16.6M | $-37.2M |
| Q4 25 | 34.3% | -19.3% | ||
| Q3 25 | 21.0% | -17.3% | ||
| Q2 25 | 27.9% | -28.4% | ||
| Q1 25 | 23.0% | -33.0% | ||
| Q4 24 | 41.8% | -41.3% | ||
| Q3 24 | 24.5% | -28.9% | ||
| Q2 24 | 15.5% | -55.9% | ||
| Q1 24 | 16.6% | -22.1% |
| Q4 25 | 0.6% | 9.9% | ||
| Q3 25 | 1.0% | 3.9% | ||
| Q2 25 | 0.5% | 2.4% | ||
| Q1 25 | 0.5% | 2.2% | ||
| Q4 24 | 0.5% | 9.4% | ||
| Q3 24 | 0.9% | 2.2% | ||
| Q2 24 | 0.7% | 2.9% | ||
| Q1 24 | 0.8% | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FROG
Segment breakdown not available.
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
